Skip to main content
. 2010 Mar 22;5(3):e9804. doi: 10.1371/journal.pone.0009804

Figure 3. PrioV3 and ICSM35 antibodies inhibit accumulation of PrPSc in ScN2a cells.

Figure 3

ScN2a cells were incubated for 24 hours at 37°C (5% CO2) with 1 or 25 µg PrioV3 and ICSM35. 25 µg NCS (Normal camel serum), and BRIC126-treated as well as untreated cells were also included. The cells were then lysed and subsequently treated with PK prior to analysis of PrPSc levels by Sandwich ELISA in triplicates. Both concentrations of PrioV3 used to treat ScN2a cells show a significant reduction in prion replication (P<0.001) when compared with the NCS control and the untreated cells. PrioV3 has also led to decreased levels of normal prion protein. ICSM35 led to a significant (P<0.001) reduction in prion replication compared to BRIC126-treated or untreated cells. Representative of three experiments.